Navigation Links
Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
Date:10/1/2008

PRINCETON, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Third Annual JMP Securities Healthcare Focus Conference being held from October 6-7, 2008 at the Le Parker Meridien in New York City. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company on Monday, October 6, 2008, from 10:00-10:30 AM (ET).

To access a live webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
2. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
3. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
4. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
5. Pharmasset Joins Russell 3000 Index
6. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
7. Pharmasset Selected to Join the NASDAQ Biotechnology Index
8. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
9. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
10. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... Patient travel is ... expertise. Colpitts Clinical Trial Travel and Expense , a division of global ... need within the biotechnology and pharmaceutical industries in the United States, Europe, and ...
(Date:2/28/2017)... ... February 28, 2017 , ... Over 8,000 recognized rare diseases ... new educational webinar on March 7, DrugDev will gather international experts to ... especially difficult area. , Webinar: Overcoming the Challenges of Rare Disease Clinical Trials, ...
(Date:2/28/2017)... , ... February 28, 2017 , ... ... high-impact life science and biotechnology companies today announced it named Joan Siefert ... be based out of Durham, NC and will begin work immediately. , Rose ...
(Date:2/28/2017)... Feb. 28, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. ... stage regenerative medicine company developing unique biologic products for ... and chronic tendon degeneration, today announced it has recently ... have committed to work with RepliCel to get the ... ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... YORK , Jan. 24, 2017 ... study of the laboratory use of nuclear magnetic ... 363 experienced end-users and profiled current practices, developments, ... years, as well as growth and opportunities. These ... Instrument suppliers, NMR instruments, needs and innovation requirements, ...
Breaking Biology News(10 mins):